We believe that biosimilar drugs are the future of health care. Our know-how allows us to manufacture high quality biosimilar drugs which offer the chance to improve the availability of drugs among the patients.
According to the latest report published by IMS Institute for Healthcare Informatics – ”Delivering on the Potential of Biosimilar Medicines”, in 2020, the value of the global market of biological drugs may amount to USD 390 bn (calculated on the basis of manufacturer net prices). This market will therefore constitute 28% of the global drug market in terms of value. It is believed that this growth will be a resultant of greater market penetration by biosimilars in the developed and developing markets, thanks to clearly defined regulatory paths.
By 2020, biosimilar drugs may potentially enter markets and replace many biological drugs, the sales of which currently amount to more than EUR 40 bn. The introduction of biosimilar drugs may result in potential savings for the health care systems in five main markets of the EU and the USA which may exceed EUR 50 bn and reach a combined value of EUR 100 bn in the next five years (IMS Institute for Healthcare Informatics – ”Delivering on the Potential of Biosimilar Medicines”).
In the next four years, considering the upcoming end of patent protection in Europe and the USA, we will be able to observe the introduction of more than 10 biological drugs from the so-called Blockbusters group (drugs generating a yearly revenue higher than USD 1 bn) with yearly sales amounting to USD 60 bn.
One of the factors stimulating the increase in sales of biotechnology drugs, especially the oncology ones, is the demographic structure of the population. It is suspected that the demand for oncology drugs will continue to successively grow because of the ongoing process of population ageing and the risk of tumours increasing with age (over 2/3 of all tumours are diagnosed among people aged 65 and above).
The latest market forecasts for biosimilar drugs indicate that the market value should reach the level of USD 32 bn in 2025. The global market for the two first monoclonal antibodies Mabion is working on (MabThera/Rituxan and Herceptin) is currently valued at USD 10 bn yearly.
Both drugs achieve very high positions in the ranking of drugs with the highest global sales (i.a. the ranking by PharmaCompass: MabThera/Rituxan – 5th place, revenue in 2015 – USD 7.1 bn, increase by USD 1.4 bn as compared to 2014; Herceptin – 8th place, revenue in 2015 – USD 6.6 bn, increase by USD 265 million as compared to 2014).
According to the estimates based on prudent assumptions, the sales value for each of the two products Mabion is working on will amount to several million dollars in the first year after launching them on the market and will increase several times during the next three years. Thanks to the technology developed at Mabion, the Company expects to achieve higher efficiency in the production of monoclonal antibodies than its competitors. The Company's products will be therefore 30-40% cheaper than the competition's offer. Currently, the costs of one year therapy with the use of monoclonal antibodies for a single patient amount to USD 50 thousand in the case of breast cancer and USD 35 thousand in the case of blood cancers.